bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P5-18-04: Bridging gaps in breast cancer care: A pilot forum for mental health professionals
Authors: Yang R , Rabinowitz B , Frank M , Schapira L , Wapnir I 
Published: February 2018

Abstract
Introduction:
Supporting the emotional needs of women diagnosed with breast cancer is a recognized priority for cancer clinicians and a core component of high quality care and survivorship programs. We hypothesized that mental health professionals would benefit from an educational program directed to enhance their practical knowledge of breast cancer.
Methods:
We designed an innovative educational forum for mental health professionals to broaden their practical knowledge regarding the physical and psychosocial effects of breast cancer. Diverse mental health professionals working in the Bay Area were invited. The day-long forum consisted of presentations and interactive discussion led by breast cancer physicians, mental health providers and patient advocates. An evaluation survey was administered at the end of the program. Descriptive statistics were performed of categorical results and open response items were aggregated.
Results:
Of 40 local pre-registrants, 18 mental health professionals (8 social workers, 6 psychologists, 3 other mental health professionals) attended. 88.2% of participants worked in a medical-based practice; 64.7% worked in an oncology-based practice. The majority of participants agreed the forum was relevant to their practice (82.3%), was well-organized (88.2%), would improve their care of patients (76.5%), and that they would recommend it to others (76.5%). The overall rating of the forum was positive (94.0%).
Conclusion:
The format and content of this forum represents a multidisciplinary educational model to enhance mental health professionals' understanding of breast cancer in order to better serve this unique patient population. Breast cancer clinicians, advocates and psychotherapists generated much enthusiasm and broad insights about meeting the psycho-emotional needs of breast cancer patients. This model can be replicated and extended to a national audience and to other cancer subpopulations.
Citation Format: Yang R, Rabinowitz B, Frank M, Schapira L, Wapnir I. Bridging gaps in breast cancer care: A pilot forum for mental health professionals [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-18-04.
Abstract P5-19-07: Defining priorities for research: Interim results of the Canadian metastatic breast cancer priority setting partnership
Authors: Nixon N , Simmons C , Lemieux J , Verma S 
Published: February 2018

Abstract
Background: Research priorities are generally determined by funders and researchers without direct involvement and input from patients and caregivers. Certain disease areas have incorporated the patient voice to determine patient driven priorities. In this study, this approach was employed to better understand the needs and priorities of metastatic breast cancer patients and their caregivers.
Methods: This study was conducted using methodology outlined by the James Lind Alliance. A steering committee of patients, physicians, patient advocates, and allied health care professionals was assembled to oversee the research study. The initial survey collected unanswered research questions from patients, caregivers, and clinicians. Responses were collected and categorized by consensus of the steering committee. Here we present the results from the national survey.
Results: Between November 2016 and April 2017, 733 responses from 311 individuals were collected (62% patients, 11% physicians, 9% caregivers or relatives, 5% nurses/allied health professionals, 2% patient organization representatives, and 10% other). The main themes for key patient priorities are: 136 (19%) related to treatment and monitoring, 78 (11%) linked lifestyle and alternative therapy, 58 (8%) regarded tumour biology, 53 (7%) regarded psychosocial aspects, 46 (6%) to diagnosis, 35 (5%) to toxicity, 24 (3%) to prevention, and 17 (2%) to young or pre-menopausal population. Two hundred and eighty-six (39%) were considered out of scope. The most frequently identified priorities included the role of alternative therapies for improving survival, the role of immune therapy for treating metastatic breast cancer, and the potential for improving outcomes with early detection/surveillance with modern treatment and diagnostic modalities.
Conclusion: Patient derived research priorities in advanced breast cancer point to an improved understanding of alternative therapies, integration of immune therapy and a focus on early detection of relapse. These priorities should be addressed by the research community to meet the needs of our patients with advanced breast cancer.
Citation Format: Nixon N, Simmons C, Lemieux J, Verma S. Defining priorities for research: Interim results of the Canadian metastatic breast cancer priority setting partnership [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-19-07.
Abstract P5-21-05: Withdrawn
Authors: Smyth LM , Oliveira M , Ciruelos E , Tamura K , El-Khoueiry A , Mita A , You B , Renouf DJ , Sablin M-P , Lluch A , Mayer IA , Bando H , Yamashita H , Ambrose H , de Bruin E , Carr TH , Corcoran C , Foxley A , Lindemann JPO , Maudsley R , Pass M , Rutkowski A , Schiavon G , Banerji U , Scaltriti M , Taylor BS , Chandarlapaty S , Baselga J , Hyman DM 
Published: February 2018

Abstract
This abstract was withdrawn by the authors.
Abstract P5-21-31: Treatment patterns and outcomes of pertuzumab in combination with trastuzumab and docetaxel as first-line treatment of metastatic HER-2 positive breast cancer : Comparison of Czech clinical registry and CLEOPATRA trial data
Authors: Studentova H , Petrakova K , Tesarova P , Buchler T , Chloupkova R , Hejduk K , Melichar B 
Published: February 2018

Abstract
Key words: pertuzumab, HER-2 positive, breast cancer
Background: The present retrospective analysis was conducted to evaluate efficacy of pertuzumab, a monoclonal antibody, used in combination with trastuzumab and docetaxel as first-line therapy for metastatic HER-2 positive breast cancer in real-world clinical practice. The database of the Czech Clinical Registry of cancer patients treated with pertuzumab was used.
Materials and methods: Data of patients included in the national registry were analyzed and the outcomes were compared with the results of the Phase III CLEOPATRA trial (Baselga et al 2012). The registry is estimated to cover at least 95% of patients treated with the regimen outside of clinical trials.
Results: : A total of 182 patients (mean age 56.5 years) were included in the present analysis. Patients had performance status of 0 (61.0%) or 1 (39%), 64.6% were postmenopausal, 62,6% had visceral disease and 36.8% received neo/adjuvant trastuzumab. The median progression-free survival of 21.2 months (95% CI 12.2–NR [not reached]) for patients included in the registry was longer, compared to 18.5 months reported in the CLEOPATRA trial, although the difference did not reach statistical significance (p=0.13). Best response was evaluable in 79.7% of patients. The overall response and disease control rates were 57.2% and 98.6%, respectively. Median overall survival has not been reached; the survival at 18 months was 86.6% (95% CI 75.7%-92.9%). Pertuzumab with trastuzumab and docetaxel was well tolerated with adverse events (AEs) attributed to pertuzumab reported in 8 patients. No AEs were life- threatening.
Conclusion: Pertuzumab in combination with trastuzumab and docetaxel is an effective and well-tolerated first-line therapy for patients with metastatic HER-2 positive breast cancer in real-world clinical practice setting. The PFS observed was consistent with data of CLEOPATRA trial.
Citation Format: Studentova H, Petrakova K, Tesarova P, Buchler T, Chloupkova R, Hejduk K, Melichar B. Treatment patterns and outcomes of pertuzumab in combination with trastuzumab and docetaxel as first-line treatment of metastatic HER-2 positive breast cancer : Comparison of Czech clinical registry and CLEOPATRA trial data [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-31.
Abstract P5-22-19: Nipple sparing mastectomy in unselect patients: Experience of an academic center in the south of Brazil
Authors: Frasson A , Zerwes F , Souza A , Rossato N , Miranda I , Trindade V , Vollbrecht B , Santos M , Viegas J 
Published: February 2018

Abstract
INTRODUCTION: Nipple sparing mastectomy (NSM) consists in the complete excision of the breast gland, mantaining the subcutaneous tissue, skin and nipple-areola complex (NAC). Recently, the NSM was developed as a therapeutic option not just for the patients that need risk-reducing surgery, but also for patients that have tumors not involving the NAC.
OBJECTIVES: Evaluate the overall survival, disease-free survival and local recurrence of the patients that underwent NSM. The only exclusion criteria for NSM was lesion at the NAC.
MATERIAL AND METHODS: Retrospective study that evaluate the number of cases of NSM performed between 2003 and 2015 in a private sector in the south of Brazil.
RESULTS: A total of 224 patients underwent NSM during the period of 2003-2015. The mean age was 47 years. From the total, 43 patients underwent risk-reducing NSM and 181 therapeutic NSM (64 unilateral and 117 bilateral). In those cases of bilateral procedures all of them underwent risk-reducing surgery on the contralateral breast (there were no bilateral cancers). Of this 181 cases, 108 (59%) have familiar history of breast cancer, considering first, second and third-degree relatives. Twenty six patients (14%) have history of previous breast cancer diagnosed. In this group of 181 patients with therapeutic NSM, 29 (16%) developed any unfavorable outcomes, 13 (7%) local recurrence, 4 (2%) ipsilateral node recurrence, 3 (1,6%) contralateral recurrence and 9 (5%) distant metastasis. None of the local recurrences occurred at the NAC, neither the cited unfavorable outcomes occurred in the risk-reducing setting. In a median follow-up of 47,7 months, the overall survival was 95% (8 deaths related to breast cancer) and the disease-free survival was 83,7%.
CONCLUSIONS: The overall survival rates of 95% at 47 months of follow-up is similar to the literature rates, that range from 93 to 97% in 5 years, depending on study's inclusion criterias. In our study, 14% of patients had previous breast cancer and 59% of patients treated for breast cancer by NSM had positive familiar history of breast cancer. This results in an unselected group of patients confirms the safety of this therapeutic method as an option for breast cancer patients.
Citation Format: Frasson A, Zerwes F, Souza A, Rossato N, Miranda I, Trindade V, Vollbrecht B, Santos M, Viegas J. Nipple sparing mastectomy in unselect patients: Experience of an academic center in the south of Brazil [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-22-19.
Abstract P6-05-04: mRNA expression of PTK6V1 and PTKV2 in human breast cancer
Authors: El Hage Chehade H , Harvey A , Wazir U , Jiang WG , Mokbel K 
Published: February 2018

Abstract
BACKGROUND:
Protein tyrosine kinase 6 (PTK6) is an intracellular protein that is upregulated in several human cancers and its localization to the plasma-membrane facilitates its various oncogenic roles in breast cancer cell proliferation, survival, and migration. The full length protein (PTK6V1) and alternative splice variant (PTK6V2) seem to play different roles with the latter being negative regulator of the former.
In this study, the level of mRNA expression of PTK6V1 and PTK6V2 were assessed in normal and malignant breast tissue using real time Q-PCR in a cohort of women with breast cancer and correlated to conventional clinico-pathological parameters and clinical outcome.
MATERIALS AND METHODS:
Breast cancer tissues (n = 127) and normal background tissues (n = 33) were collected immediately after excision during surgery. Following RNA extraction, reverse transcription was carried out and transcript levels were determined using real-time quantitative PCR and normalized against beta-actin expression. Transcript levels within the breast cancer specimens were compared to the normal background tissues and analysed against TNM stage, nodal involvement, tumour grade and clinical outcome over a 10 year follow-up period.
RESULTS:
The median copy number of transcripts of PTK6V1 were higher in malignant compared with normal breast tissue (23 vs.7) and overall increased with advancing tumour stage (374 vs. 13 for TNM3 vs. TNM1 respectively p=0.019 and 374 vs.23 for TNM3 vs. TNM2 p=0.0244). however these associations did reach statistical significance. PTK6V1 levels were associated with oestrogen receptor (ER) positivity (p = 0.061). The transcript levels were significantly higher in patients who developed recurrence (p=0.03) or died of breast cancer (p=0.003). PTK6V2 transcript levels were generally higher in normal breast tissue than in malignant tissues and decreased with increasing tumour stage and grade however these associations did not reach stastical significance. After a median follow up of 10 years, there was a trend for higher PTK6V2 expression to be associated with longer overall survival (OS) and disease free survival (DFS). PTK6V2/PTK6V1 ratio was a significant predictor of OS.
Conclusions
Our observations suggest that the two variants of PTK6 play opposing roles in mammary oncogenesis. These findings could have prognostic and therapeutic implications.
Citation Format: El Hage Chehade H, Harvey A, Wazir U, Jiang WG, Mokbel K. mRNA expression of PTK6V1 and PTKV2 in human breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-05-04.
Abstract P6-06-01: Comprehensive analysis of the DNA damage repair and maintenance pathways that regulate TNBC sensitivity to replication stress
Authors: Redwood AB , Seth S , Cai S , Piwnica-Worms H 
Published: February 2018

Abstract
Agents that induce replication stress, such as inhibitors of Chk1 or ATR, are advancing in clinical development and are being tested for treatment of various solid tumors, including triple-negative breast cancer (TNBC). While the preclinical data are encouraging, additional studies are needed to predict with precision (i) which patients will most likely benefit from these inhibitors, (ii) the genetic and proteomic contexts in which these inhibitors will provide maximum therapeutic benefit as a single agent, or require additional sensitization via combination with a targeted- or chemotherapeutic agent, and (iii) exactly which targeted/chemotherapeutic agent will provide maximum therapeutic benefit for combination with replication stress inducers. To address these challenges in TNBC, we have attempted to gain a comprehensive understanding of how the DNA damage response pathways regulate TNBC cell survival in response to Chk1 inhibitors, by performing high throughput loss-of-function screens.
We have identified genes whose loss induces death of TNBC cells in the presence of (1) CHK1i alone, (2) chemotherapy alone or (3) CHK1i plus chemotherapy. In addition, given the role of TP53 as the most frequently mutated gene in TNBC, we also determined whether distinct vulnerabilities could be identified in TNBC cells that are p53-proficient versus p53-deficient. Thus, we have also identified the top synthetic lethal interactions that are either common to both p53-proficient and p53-deficient TNBC, or unique to p53-deficient TNBC; we are currently performing in vitro studies to validate the identified mechanisms. We anticipate these studies to be applicable to other agents that induce replication stress and cell cycle checkpoint bypass. Ongoing in vivo preclinical studies, which utilize patient-derived xenografts (PDXs) of TNBC to validate these findings are expected to impact patient selection for clinical trials, and also allow us to predict which chemotherapeutic agents will be most effective for combination with different cell-cycle checkpoint inhibitors.
Citation Format: Redwood AB, Seth S, Cai S, Piwnica-Worms H. Comprehensive analysis of the DNA damage repair and maintenance pathways that regulate TNBC sensitivity to replication stress [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-06-01.
Abstract P6-06-03: Withdrawn
Authors: Cruz C , Bonache S , Montalban G , Castroviejo-Bermejo M , Llop-Guevara A , Vivancos A , Saura C , Arribas J , Díez O , Serra V , Gutiérrez-Enríquez S , Balmaña J 
Published: February 2018

Abstract
This abstract was withdrawn by the authors.
Abstract P6-07-01: Withdrawn
Authors: Jiagge EM , Wong S , Gilani R , Luthur T , Bensenhaver J , Oppong JK , Kyei I , Adjei E , Awuah B , Li J , Carpten J , Wicha M , Newman L , Merajver S 
Published: February 2018

Abstract
This abstract was withdrawn by the authors.
Abstract P6-08-01: Race and recurrence by PAM50 intrinsic subtype and ROR-PT score: The Carolina breast cancer study
Authors: Sun X , Reeder-Hayes KE , Kirk EL , Olsson L , Tse C-K , Bell MB , Earp HS , Carey LA , Perou CM , Olshan AF , Troester MA 
Published: February 2018

Abstract
Compared with white women, black women have higher breast cancer mortality. Racial differences have been reported in frequency of PAM50 intrinsic subtypes, and PAM50 intrinsic subtype is associated with prognosis. However, there is a paucity of data from large population-based studies with adequate representation of black women to evaluate its role in racial differences in breast cancer outcomes. We studied breast cancer recurrence in relation to PAM50 intrinsic subtype using data from the Carolina Breast Cancer Study Phase III (CBCS3), a large population-based prospective cohort study oversampled black women.
The current analysis included 472 black and 463 white women with stage I-III tumor and available Nanostring gene expression data for PAM50 subtype and risk of recurrence score (ROR-PT, a score calculated based on subtype, proliferation level, and tumor size; categorized as low, medium, and high). Cox proportional hazard regression was used to estimate the association of recurrence with PAM50 intrinsic subtype and ROR-PT, overall and stratified by race, adjusted for tumor size, grade, and lymph node status.
During a median follow-up of 5.78 years (range=0.39-8.22), 110 recurrent cases were identified (68 blacks and 42 whites). Consistently with previous data, basal-like tumors had the highest risk for recurrence (reference=luminal A, adjusted hazard ratio [HR]=2.85, 95% confidence interval [CI]=1.44-5.66), followed by luminal B (adjusted HR=2.35, 95%CI=1.18-4.69) and Her2-enriched (adjusted HR=2.19, 95%CI=1.01-4.74). High-ROR-PT score was also associated with increased risk in both black (adjusted HR=1.55, 95%CI=0.93-2.60) and white (adjusted HR=2.07, 95%CI=1.04-4.11). Recurrence rate for black women with medium/low ROR-PT scores was suggested higher than that for white women with similar scores (adjusted HR=1.54, 95%CI=0.69-3.42).
Our results demonstrate that PAM50 subtype and ROR-PT score are associated with breast cancer recurrence in both black and white women. Given the higher relative frequency of poor prognosis subtypes in black women, these findings help explain prognosis disparities by race.
Citation Format: Sun X, Reeder-Hayes KE, Kirk EL, Olsson L, Tse C-K, Bell MB, Earp HS, Carey LA, Perou CM, Olshan AF, Troester MA. Race and recurrence by PAM50 intrinsic subtype and ROR-PT score: The Carolina breast cancer study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-08-01.
Abstract P6-08-06: Association of body mass index (BMI) with chemotherapy administration and emergency room (ER) visits among breast cancer patients
Authors: Giordano SH , Niu J , Zhao H , Zorzi D , Chavez-Mac Gregor M 
Published: February 2018

Abstract
Background: Obese patients may be more likely to have treatment-related complications. Little is known about the association between BMI and chemotherapy-related ER visits and hospitalizations among breast cancer patients. In this study we evaluated the association between BMI and ER visits/hospitalizations in a large sample of breast cancer patients.Methods: We identified beneficiaries from the commercial MarketScan Health Risk Assessment database with breast cancer-specific claims between 2009-2014. All patients underwent mastectomy or lumpectomy and had BMI data available. BMI was categorized as normal (&lt;25), overweight (≥25 and &lt;30) and obese (≥30). Descriptive statistics were used to compare patient and treatment variables by BMI. Chemotherapy-related ER visits/hospitalizations in the 6 months after diagnosis were identified. Cox regression models were used to identify factors associated with ER visits and hospitalizations. Results: Among 7,830 patients included, 33.2% were classified as normal/underweight, 29.5% as overweight and 37.2% as obese. 2,928 (37%) patients were treated with chemotherapy. BMI differed significantly according to age, geographic region, comorbidity score, and treatment received. Among patients not treated with chemotherapy, the rates of ER visits/hospitalizations were: 11.4% for normal patients, 13.7% for overweight and 15.2% for obese patients (p=0.004). For chemotherapy-treated patients, the rates of ER visit/hospitalization were: 22.6% for normal patients, 24.3% for overweight and 30.2% for obese patients (p&lt;0.001). In the multivariable model, chemotherapy-treated patients with obesity had higher risk to have ER visits/hospitalizations (HR=1.37, 95%CI 1.14–1.64) than patients with normal BMI. No significant increase was seen among overweight patients (OR=1.09; 95%CI 0.90-1.33). Conclusions: In this cohort of patients, obesity was associated with increased risk of ER visits/hospitalizations, suggesting that careful follow–up is warranted in these patients, particularly among those receiving chemotherapy.
Citation Format: Giordano SH, Niu J, Zhao H, Zorzi D, Chavez-Mac Gregor M. Association of body mass index (BMI) with chemotherapy administration and emergency room (ER) visits among breast cancer patients [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-08-06.